{"id":12730,"date":"2026-03-10T20:34:14","date_gmt":"2026-03-10T19:34:14","guid":{"rendered":"https:\/\/event.businessfrance.fr\/next-healthcare-north-america\/?p=12730"},"modified":"2026-05-06T23:32:47","modified_gmt":"2026-05-06T21:32:47","slug":"oria-bioscience","status":"publish","type":"post","link":"https:\/\/event.businessfrance.fr\/next-healthcare-north-america\/oria-bioscience\/","title":{"rendered":"Oria Bioscience"},"content":{"rendered":"\n
\"\"<\/div><\/div>
<\/div><\/div>
\n

Oria Bioscience<\/h1><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n

Tech Bio, Pharma <\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Seed – $3,1M raised + $3.8M in non dilutive<\/p>\n\n\n\n

Goal: raising funds in 1.5 years<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Founded in 2024<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

11-50 employees<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

France 2030 Laureate<\/p>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n

<\/div>
<\/div><\/div>
\n
\n
\n

First-in-class isolated organelles for drug discovery<\/mark><\/strong><\/h3><\/div>\n\n\n\n
\n
Neurodegenerative<\/a><\/div>\n\n\n\n
Cardiology<\/a><\/div>\n\n\n\n
Metabolic<\/a><\/div>\n\n\n\n
Oncology<\/a><\/div>\n<\/div>\n\n\n\n

Oria Bioscience is a French biotechnology company specializing in the isolation and supply of native, functional organelles compatible with screening assays. Organelles are the functional units inside cells where critical biological processes occur. Lysosomes control degradation, recycling, and cellular stress responses. Mitochondria generate cellular energy and regulate metabolic and cell death pathways. The endoplasmic reticulum governs protein and lipid synthesis and maintains cellular balance. Dysfunction at the organelle level is a key driver of many diseases, making these structures essential and actionable therapeutic targets. Oria Bioscience isolates intact organelles, at high throughput, while preserving their native membranes and biological activity, enabling direct access to intracellular targets in a physiologically relevant context. Working at the organelle level reduces experimental complexity and improves data quality across early drug discovery.<\/mark><\/p>\n\n\n\n

The platform is used by pharmaceutical companies, biotechnology firms, and contract research organizations seeking more predictive research tools, delivering faster decision-making, higher ROI on candidate selection, and significant reductions in development time and costs. LYSO-Preps is Oria Bioscience\u2019s first product : a tube of ready-to-use, purified native lysosomes adapted for drug discovery and especially screening applications. Lysosomes play a central role in cellular recycling, metabolism, and stress regulation, and their dysfunction is involved in numerous diseases: Alzheimer, Parkinson’s etc… LYSO-Preps are functional lysosomes preparation with preserved biological activity, allowing direct and reliable interrogation of lysosomal targets.<\/mark><\/p>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n

CONTACT INFORMATION<\/mark><\/strong><\/h3><\/div>\n\n\n\n

Marine Moutia<\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n